Collaboration, License, Co-Promotion and Other Commercial Agreements (Tables)

6 Months Ended

Jun. 30, 2020

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

collaborative arrangements revenue and sale of API primarily attributable to transactions from these arrangements (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Collaborative Arrangements Revenue	2020		2019		2020		2019
Linaclotide Collaboration and License Agreements
AbbVie (North America)	$	86,926	$	75,498	$	158,618	$	140,283
AbbVie (Europe and other)		440		262		1,083		682
AstraZeneca (China, including Hong Kong and Macau)		187		—		519		—
Astellas (Japan)		504		—		983		—
Co-Promotion and Other Agreements:
AbbVie (VIBERZI)(1)		—		1,239		—		1,239
Alnylam (GIVLAARI)		1,061		—		2,006		—
Other		305		323		659		1,270
Total collaborative arrangements revenue	$	89,423	$	77,322	$	163,868	$	143,474
Sale of API
Linaclotide Agreements:
Astellas (Japan)	$	—	$	24,893	$	—	$	27,468
AstraZeneca (China, including Hong Kong and Macau)		9		—		5,507		—
Other		—		—		—		3
Total sale of API	$	9	$	24,893	$	5,507	$	27,471

AbbVie

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

The Company recognized collaborative arrangements revenue from the AbbVie collaboration agreement for North America during the three and six months ended June 30, 2020 and 2019 as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Collaborative arrangements revenue related to sales of LINZESS in the U.S.	$	86,503	$	74,973	$	157,645	$	139,267
Royalty revenue		423		525		973		1,016
Total collaborative arrangements revenue	$	86,926	$	75,498	$	158,618	$	140,283

Schedule of amount recorded by the Company for share of net loss related to collaborative arrangement

The following table presents selling, general and administrative costs related to the sale of LINZESS in the U.S. in accordance with the cost-sharing arrangement with AbbVie for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Selling, general and administrative costs incurred by the Company(1)	$	(3,936)	$	(10,359)	$	(12,610)	$	(20,636)

(1) Excludes an insignificant amount and approximately $0.4 million for the three and six months ended June 30, 2020, respectively, and excludes approximately $0.8 million and approximately $1.3 million for the three and six months ended June 30, 2019, respectively, related to patent prosecution and patent litigation costs recognized in connection with the collaboration agreement with AbbVie for North America.